Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | NOS1 | P29475 | 2/20 | 0.41 |
| ▸ | NOS3 | P29474 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzimidazole SCHEMBL28450502 | 0.81 | RAB9A (0.43) | PDE3BPDE3AALDH1A1MAOBNOS1 | |
| SCHEMBL10926839 | 0.78 | CA9 (0.56) | PDE3BPDE3AALDH1A1KDM4EMAPT | |
| SCHEMBL8799093 | 0.77 | PDE3B (0.77) | PDE3BPDE3AALDH1A1MAOBKDM4E | |
| SCHEMBL8787024 | 0.76 | PDE3B (0.45) | PDE3BPDE3AALDH1A1MAOBKDM4E | |
| SCHEMBL6938 | 0.72 | PDE3B (0.51) | PDE3BPDE3AALDH1A1MAOBKDM4E | |
| SCHEMBL76393 | 0.72 | ALDH1A1 (0.74) | ALDH1A1KDM4EMAPTCYP1A2CYP2A6 | |
| SCHEMBL30030322 | 0.72 | PDE3B (0.51) | PDE3BPDE3AALDH1A1MAOBKDM4E | |
| Hydrochloric Acid SCHEMBL7394595 | 0.71 | PDE3B (0.50) | PDE3BPDE3AALDH1A1MAOBKDM4E | |
| SCHEMBL2919634 | 0.71 | PDE3B (0.50) | PDE3BPDE3AALDH1A1MAOBKDM4E | |
| SCHEMBL10691670 | 0.69 | ALDH1A1 (0.48) | ALDH1A1KDM4EMAPTCA12CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173644-B2 | 3-substituted-[1,2,3]-benzotriazinone compound for enhancing glutamatergic synaptic responses | LES LABORATOIRES SERVIER (FR) | 2012-05-08 | — | — | US | disclosed |
| EP-2144506-B1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMA INC (US) | 2011-10-05 | — | — | EP | disclosed |
| US-20100137295-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | LES LABORATOIRES SERVIER (FR) | 2010-06-03 | — | — | US | disclosed |
| EP-2144506-A1 | 3-SUBSTITUTED-Ý1,2,3¨-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008085506-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | CORTEX PHARMACEUTICALS, INC. (US) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137295-A1 | 3-SUBSTITUTED-[1,2,3]-BENZOTRIAZINONE COMPOUND FOR ENHANCING GLUTAMATERGIC SYNAPTIC RESPONSES | GRIN1, GRIN3B, GRIN3A | PDE3B 1157/4885PDE3A 1134/4885ALDH1A1 3134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.